Akero Therapeutics Inc

NASDAQ:AKRO   3:47:04 PM EDT
25.77
+1.88 (+7.87%)
Other Pre-Announcement

Akero Therapeutics Reports Second Quarter 2021 Financial Results

Published: 08/13/2021 11:26 GMT
Akero Therapeutics Inc (AKRO) - Akero Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update.
Cash, Cash Equivalents and Short-term Marketable Securities for Period Ended June 30, 2021 Were $230.0 Million.
Believes Cash, Cash Equivalents and Marketable Securities Will Be Sufficient to Fund Current Operating Plan Into Q3 of 2023.
Qtrly Loss per Share $0.83.
Q2 Earnings per Share View $-0.72 -- Refinitiv Ibes Data (analyst estimates).